ConductScience.org, home

Paper25482425

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Büller HR and 9 others. N Engl J Med, 2015. Cited by 532 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Factor XI antisense oligonucleotide for prevention of venous thrombosis. Papers, record 25482425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25482425

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
PubMed
Journal
N Engl J Med
PubMed
Year
2015
PubMed
Publication types
Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
532
iCite
Relative citation ratio, by iCite
17.6
iCite
Revised in PubMed
2026-05-18
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Büller HRHarry R
2Bethune CClaudette
3Bhanot SSanjay
4Gailani DDavid
5Monia BPBrett P
6Raskob GEGary E
7Segers AAnnelise
8Verhamme PPeter
9Weitz JIJeffrey I
10FXI-ASO TKA InvestigatorsGroup

Source PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnticoagulantsMajor topic
Arthroplasty, Replacement, KneeMajor topic
Factor XIMajor topic
OligonucleotidesMajor topic
Oligonucleotides, AntisenseMajor topic
Postoperative ComplicationsMajor topic
Venous ThrombosisMajor topic
Adult
Aged
Blood Coagulation
Clinical Protocols
Enoxaparin
Female
Hemorrhage
Humans
Length of Stay
Male
Middle Aged
Partial Thromboplastin Time

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 HL058837NHLBI NIH HHSUnited StatesR01HL058837PubMed and NIHNIH RePORTER
R01 HL081326NHLBI NIH HHSUnited StatesR01HL081326PubMed and NIHNIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01713361Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee ArthroplastyDerived from the trialYes

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in25,482,334Making (anti)sense of factor XI in thrombosis.https://conductscience.org/library/papers/25482334PubMed
Comment in25,533,800Anticoagulation therapy: Reducing factor XI with antisense oligonucleotides superior to endoxaparin for postoperative venous thromboembolism.https://conductscience.org/library/papers/25533800PubMed
Comment in25,901,434Factor XI antisense oligonucleotide for venous thrombosis.https://conductscience.org/library/papers/25901434PubMed
Comment in25,901,435Factor XI antisense oligonucleotide for venous thrombosis.https://conductscience.org/library/papers/25901435PubMed
Comment in25,901,436Factor XI antisense oligonucleotide for venous thrombosis.https://conductscience.org/library/papers/25901436PubMed

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122,315,265Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest2012https://conductscience.org/library/papers/22315265PubMed
220,807,891Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.Blood2010https://conductscience.org/library/papers/20807891PubMed
323,615,791Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.Thromb Haemost2013https://conductscience.org/library/papers/23615791PubMed
423,559,626Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.Arterioscler Thromb Vasc Biol2013https://conductscience.org/library/papers/23559626PubMed
522,246,038Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.Blood2012https://conductscience.org/library/papers/22246038PubMed
620,005,807Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.Cell2009https://conductscience.org/library/papers/20005807PubMed
719,617,576Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.Blood2009https://conductscience.org/library/papers/19617576PubMed
818,945,968Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.Blood2009https://conductscience.org/library/papers/18945968PubMed
918,288,180Triggers, targets and treatments for thrombosis.Nature2008https://conductscience.org/library/papers/18288180PubMed
1020,723,033A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.J Thromb Haemost2010https://conductscience.org/library/papers/20723033PubMed
1121,057,700Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis.Thromb Haemost2011https://conductscience.org/library/papers/21057700PubMed
1224,366,358Thrombosis: tangled up in NETs.Blood2014https://conductscience.org/library/papers/24366358PubMed
1310,706,899High levels of coagulation factor XI as a risk factor for venous thrombosis.N Engl J Med2000https://conductscience.org/library/papers/10706899PubMed
141,652,157Factor XI activation in a revised model of blood coagulation.Science1991https://conductscience.org/library/papers/1652157PubMed
1516,961,605Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.J Thromb Haemost2006https://conductscience.org/library/papers/16961605PubMed
1617,405,864Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17405864PubMed
1717,855,670Idraparinux versus standard therapy for venous thromboembolic disease.N Engl J Med2007https://conductscience.org/library/papers/17855670PubMed

Cited by281

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 532 citations.

PMIDTitleJournalYearIn PapersSource
42,936,593Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42936593PubMed
42,936,574Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42936574PubMed
42,936,046Perspectives: what we are learning from factor XI/factor XIa inhibitor trials.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42936046PubMed
42,898,680Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors.Front Immunol2026https://conductscience.org/library/papers/42898680PubMed
42,881,892Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications.J Clin Med2026https://conductscience.org/library/papers/42881892PubMed
42,628,751Structural insights into the exosite-mediated activation of factor IX by factor XIa using cryogenic electron microscopy.J Thromb Haemost2026https://conductscience.org/library/papers/42628751PubMed
42,318,380Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model.Blood Vessel Thromb Hemost2026https://conductscience.org/library/papers/42318380PubMed
42,275,249Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).Blood2026https://conductscience.org/library/papers/42275249PubMed
42,260,521Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations.Thromb J2026https://conductscience.org/library/papers/42260521PubMed
42,026,656Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.Cardiooncology2026https://conductscience.org/library/papers/42026656PubMed
42,022,599Asundexian Versus Apixaban in Patients With Atrial Fibrillation.Health Sci Rep2026https://conductscience.org/library/papers/42022599PubMed
41,977,337Pharmacological Management of Thrombosis: Current State and Future Strategies.Int J Mol Sci2026https://conductscience.org/library/papers/41977337PubMed
41,899,496From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review.Cancers (Basel)2026https://conductscience.org/library/papers/41899496PubMed
41,879,908Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials.Adv Ther2026https://conductscience.org/library/papers/41879908PubMed
41,802,667Targeting factor XI for venous thromboembolism prevention: a tale of 2 antibodies.J Thromb Haemost2026https://conductscience.org/library/papers/41802667PubMed
41,677,103Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation.Clin Cardiol2026https://conductscience.org/library/papers/41677103PubMed
41,581,095Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions.Am J Cardiovasc Drugs2026https://conductscience.org/library/papers/41581095PubMed
41,512,172RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran).Blood Adv2026https://conductscience.org/library/papers/41512172PubMed
41,304,947Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41304947PubMed
41,222,225Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events.CPT Pharmacometrics Syst Pharmacol2025https://conductscience.org/library/papers/41222225PubMed

See all 281 cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
F102,159PubTator's text mininghttps://conductscience.org/library/genes/2159NCBI Gene
F112,160PubTator's text mininghttps://conductscience.org/library/genes/2160NCBI Gene
F122,161PubTator's text mininghttps://conductscience.org/library/genes/2161NCBI Gene
F22,147PubTator's text mininghttps://conductscience.org/library/genes/2147NCBI Gene
RNASEH1246,243PubTator's text mininghttps://conductscience.org/library/genes/246243NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25482425

GET https://conductscience.org/api/papers/v1/25482425/cited_by?page=2